Ock Minsu, Park Jeong-Yeol, Son Woo-Seung, Lee Hyeon-Jeong, Kim Seon-Ha, Jo Min-Woo
Department of Preventive Medicine, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 138-736, South Korea.
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Health Qual Life Outcomes. 2016 Nov 28;14(1):163. doi: 10.1186/s12955-016-0566-8.
A cost-utility study of a human papilloma virus (HPV) vaccine requires that the utility weights for HPV-related health states (i.e., cervical intraepithelial neoplasia (CIN), cervical cancer, and condyloma) be evaluated. The aim of the present study was to determine the utility weights for HPV-related health states.
Hypothetical standardised health states related to HPV were developed based on patient education material and previous publications. To fully reflect disease progression from diagnosis to prognosis, each health state comprised four parts (diagnosis, symptoms, treatment, and progression and prognosis). Nine-hundred members from the Korean general population evaluated the HPV-related health states using a visual analogue scale (VAS) and a standard gamble (SG) approach, which were administered face-to-face via computer-assisted interview. The mean utility values were calculated for each HPV-related health state.
According to the VAS, the highest utility (0.73) was HPV-positive status, followed by condyloma (0.66), and CIN grade I (0.61). The lowest utility (0.18) was cervical cancer requiring chemotherapy without surgery, followed by cervical cancer requiring chemoradiation therapy (0.42). SG revealed that the highest utility (0.83) was HPV-positive status, followed by condyloma (0.78), and CIN grade I (0.77). The lowest utility (0.43) was cervical cancer requiring chemotherapy without surgery, followed by cervical cancer requiring chemoradiation therapy (0.60).
This study was based on a large sample derived from the general Korean population; therefore, the calculated utility weights might be useful for evaluating the economic benefit of cancer screening and HPV vaccination programs.
一项关于人乳头瘤病毒（HPV）疫苗的成本效用研究要求对HPV相关健康状态（即宫颈上皮内瘤变（CIN）、宫颈癌和尖锐湿疣）的效用权重进行评估。本研究的目的是确定HPV相关健康状态的效用权重。
基于患者教育材料和以往出版物，制定了与HPV相关的假设标准化健康状态。为了充分反映从诊断到预后的疾病进展，每个健康状态包括四个部分（诊断、症状、治疗以及进展和预后）。来自韩国普通人群的900名成员使用视觉模拟量表（VAS）和标准博弈法（SG）对HPV相关健康状态进行评估，评估通过计算机辅助访谈面对面进行。计算每个HPV相关健康状态的平均效用值。
根据VAS，效用最高的是HPV阳性状态（0.73），其次是尖锐湿疣（0.66）和CIN 1级（0.61）。效用最低的是需要化疗而非手术的宫颈癌（0.18），其次是需要放化疗的宫颈癌（0.42）。SG显示，效用最高的是HPV阳性状态（0.83），其次是尖锐湿疣（0.78）和CIN 1级（0.77）。效用最低的是需要化疗而非手术的宫颈癌（0.43），其次是需要放化疗的宫颈癌（0.60）。
本研究基于来自韩国普通人群的大样本；因此，计算出的效用权重可能有助于评估癌症筛查和HPV疫苗接种计划的经济效益。
